Old and re-purposed drugs for the treatment of COVID-19
Shio‐Shin Jean, Po‐Ren Hsueh
Abstract
: Although strong evidence of well-designed randomized controlled studies regarding COVID-19 therapy is presently lacking, remdesivir, teicoplanin, hydroxychloroquine (not in combination with azithromycin), and ivermectin might be effective antiviral drugs and are deemed promising candidates for controlling SARS-CoV-2. In addition, tocilizumab might be considered as the supplementary treatment for COVID-19 patients with cytokine release syndrome. In future, clinical trials regarding a combination of potentially effective drugs against SARS-CoV-2 need to be conducted to establish the optimal regimen for the treatment of patients with moderate-to-severe COVID-19.
Topics & Concepts
Coronavirus disease 2019 (COVID-19)PandemicSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Respirator2019-20 coronavirus outbreakMedicineCoronavirusBetacoronavirusIntensive care medicineVirologyDiseaseMedical emergencyOutbreakInfectious disease (medical specialty)Internal medicineComposite materialMaterials scienceCOVID-19 Clinical Research StudiesLong-Term Effects of COVID-19SARS-CoV-2 and COVID-19 Research